Search | Clinical Trials Finder

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions: Relugolix Pill, Ritonavir, Itraconazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Transplantation
Interventions: Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: HIV-1 Infection, HCV Infection
Interventions: E/C/F/TAF, F/R/TAF, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: Smallpox
Interventions: Tecovirimat, Smallpox and Mpox Vaccine, Placebo; Drug · Other
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 42 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Omaha, Nebraska • Columbus, Ohio

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: HIV-1, HIV Infections
Interventions: TMC114, Ritonavir; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: PPI-461, Placebo; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Sars-CoV-2, Covid19
Interventions: BLD-2660; Drug
Lead sponsor: Blade Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 27
States / cities: Irvine, California • Los Angeles, California • San Jose, California + 23 more

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Atazanavir+ritonavir, Lopinavir+ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Valganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
Interventions: ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab; Biological · Drug · Radiation
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Anaheim, California • Coronado, California • San Jose, California + 7 more

Conditions: Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions: Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 11
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: HIV Infections
Interventions: DTG/3TC FDC, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more

Conditions: Respiratory Syncytial Virus
Interventions: Presatovir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 20 more

Conditions: Healthy
Interventions: Placebo, JNJ-64281802 High dose, JNJ-64281802 Medium dose, JNJ-64281802 Low dose, JNJ-64281802 Dosing Regimen X, JNJ-64281802 Dosing Regimen Y, JNJ-64281802 Dosing Regimen Z; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Herpes Simplex Virus
Interventions: Novel Antiviral Drug, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 98 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Chronic Hepatitis B Virus
Interventions: Stop NA therapy; Other
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 67 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza A Virus
Interventions: JNJ-63623872, Placebo, Oseltamivir; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Fresno, California • Long Beach, California • Stanford, California + 11 more

Search by objective public record fields.

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection